Enovis CORP (ENOV)
Health Care / Health Care Equipment
S&P SmallCap 600$23.37
Scores poorly across most models. Proceed with caution.
Avoid
Score based on 4 of 5 models — moderate confidence
Is Enovis CORP a Good Investment in 2026?
Enovis CORP (ENOV) scores 2.0 out of 10 on AlphaStocks' composite model, earning a Avoid rating. The Piotroski model is the most favorable, rating Enovis CORP as Neutral. However, the Greenblatt Magic Formula model rates it Caution — Bottom half (rank 95%). Enovis CORP currently trades above its estimated fair value of $21, suggesting limited upside at current prices. Enovis CORP ranks #1089 out of 1127 stocks in the Health Care sector.
This summary is algorithmically generated and is not financial advice.
Key Metrics
Estimated Fair Value
Trading near estimated fair value.
Model-based estimate, not a price target.
5-Model Analysis
Each model evaluates this stock from a different angle. Combined, they form the composite score above.
Piotroski
Neutral
4/9
Buffett
Caution
Business quality & competitive moat
Graham
Neutral
Price vs intrinsic value
Lynch
Neutral
Growth rate vs price (PEG)
Greenblatt
Caution
Bottom half (rank 95%)
Frequently Asked Questions
Is Enovis CORP (ENOV) a good investment?
What is Enovis CORP's Piotroski F-Score?
Is ENOV overvalued or undervalued?
How does ENOV compare to other Health Care stocks?
What do investment models say about ENOV?
Similar Stocks
Compare ENOV with
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer